BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 17225279)

  • 1. Anti-HIV agents. Dueling nukes: AZT + 3TC vs. tenofovir + FTC.
    TreatmentUpdate; 2005; 17(5):5-7. PubMed ID: 17225279
    [No Abstract]   [Full Text] [Related]  

  • 2. Meeting notes from ICAAC. Tenofovir + emtricitabine vs. AZT + 3TC.
    Feinberg J
    AIDS Clin Care; 2005 Jan; 17(1):7. PubMed ID: 15717373
    [No Abstract]   [Full Text] [Related]  

  • 3. Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients.
    Masquelier B; Neau D; Boucher S; Lavignolle-Aurillac V; Schrive MH; Recordon-Pinson P; Ragnaud JM; Fleury H
    Antivir Ther; 2006; 11(6):827-30. PubMed ID: 17310827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial.
    Martin A; Bloch M; Amin J; Baker D; Cooper DA; Emery S; Carr A
    Clin Infect Dis; 2009 Nov; 49(10):1591-601. PubMed ID: 19842973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical experience with nevirapine combined with tenofovir plus emtricitabine or lamivudine-containing regimens in HIV-infected subjects.
    Smith DE; Chan DJ; Maruszak H; Jeganathan S
    Int J STD AIDS; 2011 Apr; 22(4):228-30. PubMed ID: 21515757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The art of managing human immunodeficiency virus infection: a balancing act.
    Reiss P
    Clin Infect Dis; 2009 Nov; 49(10):1602-4. PubMed ID: 19842978
    [No Abstract]   [Full Text] [Related]  

  • 7. Tenofovir DF and emtricitabine vs. zidovudine and lamivudine.
    Jenny-Avital ER
    N Engl J Med; 2006 Jun; 354(23):2506-8; author reply 2506-8. PubMed ID: 16764056
    [No Abstract]   [Full Text] [Related]  

  • 8. Combination antiretroviral therapy with tenofovir, emtricitabine or lamivudine, and nevirapine.
    Redfield RR; Morrow JS
    Clin Infect Dis; 2008 Oct; 47(7):984-5. PubMed ID: 18778234
    [No Abstract]   [Full Text] [Related]  

  • 9. Meeting notes from ICAAC. Tenofovir + ddI: a combination to avoid.
    Sax PE
    AIDS Clin Care; 2005 Jan; 17(1):6-7. PubMed ID: 15717372
    [No Abstract]   [Full Text] [Related]  

  • 10. Potency of tenofovir in chronic hepatitis B: mono or combination therapy?
    Reijnders JG; Janssen HL
    J Hepatol; 2008 Mar; 48(3):383-6. PubMed ID: 18191272
    [No Abstract]   [Full Text] [Related]  

  • 11. Minor emtricitabine intolerance in treatment-stable patients switched from tenofovir/lamivudine to a fixed-dose combination of tenofovir/emtricitabine (Truvada).
    Palacios R; TerrĂ³n A; Hidalgo A; Rivero A; Santos J;
    J Antimicrob Chemother; 2008 Feb; 61(2):462-3. PubMed ID: 18156608
    [No Abstract]   [Full Text] [Related]  

  • 12. 96-week CASTLE data show similar efficacy results.
    AIDS Patient Care STDS; 2008 Nov; 22(11):918. PubMed ID: 19043840
    [No Abstract]   [Full Text] [Related]  

  • 13. Anti-HIV agents. Abacavir--as good as AZT?
    TreatmentUpdate; 2003 Oct; 15(6):3-4. PubMed ID: 17216861
    [No Abstract]   [Full Text] [Related]  

  • 14. The efficacy of combined zidovudine and lamivudine compared with that of combined zidovudine, lamivudine and nelfinavir in asymptomatic and early symptomatic HIV-infected children.
    Moolasart P; Likanonsakul S
    Southeast Asian J Trop Med Public Health; 2002 Jun; 33(2):280-7. PubMed ID: 12236426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abacavir/3TC vs. tenofovir/FTC: interim results from ACTG 5202.
    Albrecht H
    AIDS Clin Care; 2008 Apr; 20(4):28. PubMed ID: 19271262
    [No Abstract]   [Full Text] [Related]  

  • 16. [First line therapy. Tenofovir DF/emtricitabine--the potent backbone].
    MMW Fortschr Med; 2008 Apr; 150 Spec No 1():12-4. PubMed ID: 19024908
    [No Abstract]   [Full Text] [Related]  

  • 17. Tenofovir regimen compared with Combivir.
    AIDS Patient Care STDS; 2005 Jan; 19(1):59-60. PubMed ID: 15700398
    [No Abstract]   [Full Text] [Related]  

  • 18. New once-daily HIV combination better tolerated.
    Expert Rev Anti Infect Ther; 2004 Dec; 2(6):826. PubMed ID: 15566325
    [No Abstract]   [Full Text] [Related]  

  • 19. The use of a triple nucleoside-nucleotide regimen for nonoccupational HIV post-exposure prophylaxis.
    Winston A; McAllister J; Amin J; Cooper DA; Carr A
    HIV Med; 2005 May; 6(3):191-7. PubMed ID: 15876286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
    Rey D; Hoen B; Chavanet P; Schmitt MP; Hoizey G; Meyer P; Peytavin G; Spire B; Allavena C; Diemer M; May T; Schmit JL; Duong M; Calvez V; Lang JM
    J Antimicrob Chemother; 2009 Feb; 63(2):380-8. PubMed ID: 19036752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.